Heterologous Production of Antimicrobial Peptides: Notes to Consider.
Masoumeh KordiParnian Ghaedi TalkhouncheHelia VahediNaser FarrokhiMaryam TabarzadPublished in: The protein journal (2024)
Heavy and irresponsible use of antibiotics in the last century has put selection pressure on the microbes to evolve even faster and develop more resilient strains. In the confrontation with such sometimes called "superbugs", the search for new sources of biochemical antibiotics seems to have reached the limit. In the last two decades, bioactive antimicrobial peptides (AMPs), which are polypeptide chains with less than 100 amino acids, have attracted the attention of many in the control of microbial pathogens, more than the other types of antibiotics. AMPs are groups of components involved in the immune response of many living organisms, and have come to light as new frontiers in fighting with microbes. AMPs are generally produced in minute amounts within organisms; therefore, to address the market, they have to be either produced on a large scale through recombinant DNA technology or to be synthesized via chemical methods. Here, heterologous expression of AMPs within bacterial, fungal, yeast, plants, and insect cells, and points that need to be considered towards their industrialization will be reviewed.
Keyphrases
- gram negative
- immune response
- saccharomyces cerevisiae
- induced apoptosis
- amino acid
- poor prognosis
- cell free
- cell cycle arrest
- multidrug resistant
- escherichia coli
- microbial community
- single molecule
- working memory
- circulating tumor
- oxidative stress
- health insurance
- antimicrobial resistance
- binding protein
- endoplasmic reticulum stress
- circulating tumor cells
- cell proliferation